⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514065 | 1.00 | — | — | |
| SCHEMBL1969954 | 0.83 | NOS2 (0.45) | — | |
| SCHEMBL9579255 | 0.80 | — | — | |
| SCHEMBL4630954 | 0.80 | — | — | |
| SCHEMBL887204 | 0.80 | — | — | |
| SCHEMBL17929302 | 0.80 | — | — | |
| D-Proline SCHEMBL18493080 | 0.79 | NOS2 (0.45) | — | |
| Proline SCHEMBL3097543 | 0.79 | NOS2 (0.45) | — | |
| Proline SCHEMBL1675389 | 0.79 | NOS2 (0.45) | — | |
| SCHEMBL4012939 | 0.79 | PRCP (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8709999-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |